top of page

NEWS & PUBLICATIONS

08/27/2024

Tern Therapeutics Launches with $15 Million Financing and Pipeline in CLN2 Batten Disease

02/10/2025

Tern Therapeutics Advances Pipeline and Presents Positive Clinical Data for TTX-381 and TTX-181 Gene Therapies for CLN2 Batten Disease at 21st Annual WORLDSymposium

02/27/2025

Tern Therapeutics Issues CLN2 Batten Community Letter, February 2025

04/08/2025

Tern Therapeutics Receives US FDA Fast Track Designation for TTX-381 Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease

bottom of page